CTO1681

CTO1681 is an investigational small molecule drug developed by CytoAgents for the prevention and treatment of cytokine release syndrome (CRS), particularly in patients undergoing CAR T-cell therapy for lymphoma. It acts as a potent agonist of the EP4 receptor, thereby modulating the NF-kB signaling pathway to reduce excessive cytokine production without completely suppressing immune function. This mechanism allows CTO1681 to limit harmful inflammation while preserving necessary immune responses. The drug is orally available and has demonstrated a strong safety profile in clinical trials. Its broad anti-inflammatory action positions it as a potential new standard of care for CRS and related inflammatory conditions[1][4][7][8].

Other names

Beraprost analogue